BOSTON, MASSACHUSETTS
2021
Pharmaceuticals
2
$9.75M
Every filing
| Filed | Type | Amount sold | Total offering | Records |
|---|---|---|---|---|
| 2026-10-20 | New offering first sale 2026-10-08 | $5.50M | $5.50M | details · SEC filing |
| 2025-05-15 | New offering first sale 2025-04-17 | $4.25M | $8M | SEC filing |
Watch Crosslink Therapeutics Inc.
Get an email when Crosslink Therapeutics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
What do you want to do with Crosslink Therapeutics Inc.?
Who to contact
- Ronald Seidel, III — Executive Officer, Director
- Andrew King — Director
- Lou Tartaglia — Director
- Rodolfo Chaparro — Director
- David Fallace — Director
- Cameron Gallagher — Director
- Round: Form D filed 2026-10-20
- Amount sold: $5.50M
- Industry: Pharmaceuticals
- Founded: 2021
- Based: BOSTON, MASSACHUSETTS
People listed
- Ronald Seidel, III — Executive Officer, Director
- Andrew King — Director
- Lou Tartaglia — Director
- Rodolfo Chaparro — Director
- David Fallace — Director
- Cameron Gallagher — Director
- Filing: Form D filed 2026-10-20
- Amount sold: $5.50M
- Industry group: Pharmaceuticals
- Year formed: 2021
- Based: BOSTON, MASSACHUSETTS
- Entity type: Corporation
We'll show it in your MentionFox inbox when Crosslink Therapeutics Inc. raises, hires or launches. No email unless you switch it on.
Watch Crosslink Therapeutics Inc. →Want the whole picture on Crosslink Therapeutics Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Crosslink Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Crosslink Therapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
How the total is counted: the amount sold on each new offering, added together. Amendments are left out, because an amendment restates an offering already counted. A filing whose figures have not been read yet shows a dash and adds nothing.
Every figure here is read from Crosslink Therapeutics Inc.'s own filings with the SEC. The people those filings name are on the team page.